Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.51 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.50 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | GLRA3 | O75311 | 1/20 | 0.47 |
| ▸ | GLRB | P48167 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | XDH | P47989 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30444179 | 1.00 | TSHR (0.52) | TSHRLOXL2CYP4F2CYP4A11RAB9A | |
| SCHEMBL13132575 | 0.84 | MEN1 (0.65) | RAB9AALDH1A1NPC1MEN1KMT2A | |
| SCHEMBL13132745 | 0.84 | MEN1 (0.61) | RAB9AALDH1A1NPC1MEN1KMT2A | |
| SCHEMBL1800821 | 0.84 | TSHR (0.53) | TSHRLOXL2CYP4F2CYP4A11RAB9A | |
| Methyl Benzoate SCHEMBL28358400 | 0.84 | TSHR (0.70) | TSHRRAB9APOLBALDH1A1NPC1 | |
| SCHEMBL23380281 | 0.82 | EGFR (0.55) | TSHRGLRA3GLRBMEN1KMT2A | |
| SCHEMBL10411912 | 0.82 | ALDH1A1 (0.52) | TSHRLOXL2CYP4F2CYP4A11RAB9A | |
| SCHEMBL16618914 | 0.82 | TSHR (0.52) | TSHRLOXL2CYP4F2CYP4A11RAB9A | |
| SCHEMBL3851983 | 0.82 | TSHR (0.52) | TSHRLOXL2CYP4F2CYP4A11RAB9A | |
| SCHEMBL60040 | 0.82 | MRGPRX4 (0.56) | TSHRLOXL2CYP4F2CYP4A11RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120132861-A | Copper-based high-entropy alloy material and preparation method and application thereof | 温州大学新材料与产业技术研究院 | 2025-06-13 | — | — | CN | claimed |
| EP-3051946-B1 | USE OF SUBSTITUTED DIHYDROOXINDOLYLSULFONAMIDES OR THEIR SALTS FOR INCREASING STRESS TOLERANCE IN PLANTS | BAYER CROPSCIENCE AG (DE) | 2017-11-29 | — | — | EP | claimed |
| EP-0050428-A1 | Ethynylated aromatic compounds and process for making same | Hughes Aircraft Company (US) | 1982-04-28 | — | — | EP | claimed |
| EP-4712967-A2 | G-PROTEIN COUPLED RECEPTOR ANTAGONIST | Enveda Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-12441726-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250304576-A1 | IKK INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2025-10-02 | — | — | US | disclosed |
| US-12351570-B2 | Disubstituted alkyne derivatives | MERCK PATENT GMBH (DE) | 2025-07-08 | — | — | US | disclosed |
| CN-120132861-A | Copper-based high-entropy alloy material and preparation method and application thereof | 温州大学新材料与产业技术研究院 | 2025-06-13 | — | — | CN | disclosed |
| EP-4522597-A1 | IKK INHIBITORS | Cancer Research Technology Limited (GB) | 2025-03-19 | — | — | EP | disclosed |
| CN-119562945-A | IKK inhibitors | 癌症研究技术有限公司 | 2025-03-04 | — | — | CN | disclosed |
| WO-2024239000-A2 | G-PROTEIN COUPLED RECEPTOR ANTAGONIST | ENVEDA THERAPEUTICS, INC. (US) | 2024-11-21 | — | — | WO | disclosed |
| US-5624943-A | Pyridine compounds which are useful as leukotriene-B4 -antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-04-29 | — | — | US | disclosed |
| US-5614634-A | Leukotriene-B4 derivatives, process for their production and their use as pharmaceutical agents | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-03-25 | — | — | US | disclosed |
| US-5440044-A | Leukotriene-B4 derivatives, process for their production and their use as pharmaceutical agents | SCHERING AKTIENGESELLSCHAFT (DE) | 1995-08-08 | — | — | US | disclosed |
| EP-0575494-A4 | — | — | 1994-04-20 | — | — | EP | disclosed |
| EP-0575494-A1 | LEUKOTRIENE ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-12-29 | — | — | EP | disclosed |
| WO-1993022285-A1 | LEUKOTRIENE ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-11-11 | — | — | WO | disclosed |
| WO-1992016104-A1 | LEUKOTRIENE ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1992-10-01 | — | — | WO | disclosed |
| US-4465833-A | ALKYNYLATION HALOGENATED BENZENE COMPOUND IN PRESENCE OF METAL CATALYST | HUGHES AIRCRAFT COMPANY (US) | 1984-08-14 | — | — | US | disclosed |
| EP-0050428-A1 | Ethynylated aromatic compounds and process for making same | Hughes Aircraft Company (US) | 1982-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304576-A1 | IKK INHIBITORS | NFKBIA, IKBKE, IKBKB | TSHR 3502/4885LOXL2 4478/4885CYP4F2 4484/4885 |
| US-12351570-B2 | Disubstituted alkyne derivatives | BRCA1, MYC, PCNA | TSHR 3500/4885LOXL2 1039/4885CYP4F2 2833/4885 |
| US-12441726-B2 | Compounds and uses thereof | VHL, CLN6, TFEB | TSHR 4351/4885LOXL2 2917/4885CYP4F2 2084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.